Blueprint Medicines Corporation
BPMCDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
regorafenib
GIST
Elenestinib
Indolent Systemic Mastocytosis
avapritinib
Solid Tumor, Unspecified, Child
BLU-808
Chronic Inducible Urticaria
BLU-924
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
regorafenib | Phase 3 | GIST | - | - |
Elenestinib | Phase 3 | Indolent Systemic Mastocytosis | - | - |
avapritinib | Phase 3 | Solid Tumor, Unspecified, Child | - | - |
BLU-808 | Phase 2 | Chronic Inducible Urticaria | - | - |
BLU-924 | Phase 2 | Advanced Solid Tumor | - | - |
Indolent Systemic Mastocytosis
2 drugs in this indication
GIST
1 drug in this indication
Solid Tumor, Unspecified, Child
1 drug in this indication
Chronic Inducible Urticaria
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Blueprint Medicines Corporation's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Blueprint Medicines Corporation's (BPMC) pipeline across Phase 3, Phase 2. Its lead program is regorafenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Blueprint Medicines Corporation's next FDA catalyst?→
Blueprint Medicines Corporation's (BPMC) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BPMC biotech catalysts?→
Add BPMC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Blueprint Medicines Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.